Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group.

PURPOSE Although tumor resection is the mainstay of treatment for localized neuroblastoma, there are no established guidelines indicating which patients should be operated on immediately and which should undergo surgery after tumor reduction with chemotherapy. In an effort to develop such guidelines, the LNESG1 study defined surgical risk factors (SRFs) based on the imaging characteristics. PATIENTS AND METHODS A total of 905 patients with suspected localized neuroblastoma were registered by 10 European countries between January 1995 and October 1999; 811 of 905 patients were eligible for this analysis. RESULTS Information on SRFs was obtained for 719 of 811 patients; 367 without and 352 with SRFs. Of these 719 patients, 201 patients (four without and 197 with SRFs) underwent biopsy only. An attempt at tumor excision was made in 518 patients: 363 of 367 patients without and 155 of 352 patients with SRFs (98.9% v 44.0%). Complete excision was achieved in 271 of 363 patients without and in 72 of 155 patients with SRF (74.6% v 46.4%), near-complete excision was achieved in 81 and 61 patients (22.3% v 39.3%), and incomplete excision was achieved in 11 and 22 patients (3.0% v 14.2%), respectively. There were two surgery-related deaths. Nonfatal surgery-related complications occurred in 45 of 518 patients (8.7%) and were less frequent in patients without SRFs (5.0% v 17.4%). Associated surgical procedures were also less frequent in patients without SRFs (1.6% v 9.7%). CONCLUSION The adoption of SRFs as predictors of adverse surgical outcome was validated because their presence was associated with lower complete resection rate and greater risk of surgery-related complications. Additional studies aiming to better define the surgical approach to localized neuroblastoma are warranted.

[1]  A. Horiuchi,et al.  Thoracic neuroblastoma: outcome of incomplete resection , 2004, Pediatric Surgery International.

[2]  A. Ruíz,et al.  The role of surgery in stage IV neuroblastoma. , 2002, Journal of pediatric surgery.

[3]  A. Donfrancesco,et al.  Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Bruzzi,et al.  Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: does it affect the clinical course? , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  O. Delattre,et al.  High‐dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification , 2004, Cancer.

[6]  A. Donfrancesco,et al.  Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Bruzzi,et al.  Disseminated neuroblastoma (stage IV and IV‐S) in the first year of life. Outcome related to age and stage , 1992, Cancer.

[8]  K. Matthay,et al.  Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. , 2004, Journal of pediatric surgery.

[9]  J. Shuster,et al.  Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Shamberger,et al.  The risk of nephrectomy during local control in abdominal neuroblastoma. , 1998, Journal of pediatric surgery.

[11]  M. Iwakawa,et al.  Complete resection is not required in patients with neuroblastoma under 1 year of age. , 1998, Journal of pediatric surgery.

[12]  F. Berthold,et al.  New Definition of Low-Risk Neuroblastoma Using Stage, Age, and 1p and MYCN Status , 2004, Journal of pediatric hematology/oncology.

[13]  B. Kushner,et al.  Neuroblastoma: a disease requiring a multitude of imaging studies. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  E. Kiely The surgical challenge of neuroblastoma. , 1994, Journal of pediatric surgery.

[15]  M. Quaglia Surgical Management of Neuroblastoma , 2001 .

[16]  H. Shimada,et al.  The role of surgery in localized neuroblastoma. , 1985, Journal of pediatric surgery.

[17]  H. B. Marsden,et al.  Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. , 1984, Journal of the National Cancer Institute.

[18]  G. Leverger,et al.  Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP). , 1998, British Journal of Cancer.

[19]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[20]  A. Donfrancesco,et al.  Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Shuster,et al.  Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited postoperative chemotherapy: a Pediatric Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Stram,et al.  Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.